Latest news with #Lantus
Yahoo
24-04-2025
- Business
- Yahoo
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The performance was driven by pharma launches, Dupixent, and Lantus, while legacy medicines were lower. Vaccine sales were broadly stable, including lower sales of Beyfortus. Also Read: The French drugmaker reported adjusted EPS of 1.79 euros or 94 cents per ADS, missing the consensus of 95 cents, up 17% (+15.7% on constant currency). Sales of Dupixent, Sanofi's blockbuster eczema drug, rose 20.3% to 3.5 billion euros due to strong volume growth across all indications and regions. The first COPD launches are underway. Pharma launches increased 43.8% to 847 million euros, led by Altuviiio (hemophilia drug), Nexviazyme (Pompe disease), Sarclisa (multiple myeloma), and Rezurock (chronic graft-versus-host disease). Vaccine sales were up 11.4% to 1.3 billion euros, driven by favorable Beyfortus (RSV) phasing and geographical roll-out. Beyfortus sales were 284 million euros, driven by additional sales in the Northern Hemisphere, particularly Germany and Japan. Polio/Pertussis/Hib (PPH) primary and booster vaccine sales were 668 million euros and increased by 3.8%, primarily due to demand for boosters to re-vaccinate adolescents and adults. 'We had a strong start in 2025 with sales growth of 9.7%, benefiting from investments in innovation and a favorable base of comparison. Our focus on pipeline value delivered further growth for Sanofi with sales from launches of new medicines and vaccines growing by 46.5%,' said Paul Hudson, Chief Executive Officer. Guidance: Sanofi confirmed its 2025 guidance. In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit level. On Wednesday, Innate Pharma SA (NASDAQ:IPHA) reviewed their January 2016 Research Collaboration and License Agreement with Sanofi: As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR'514/IPH6401 (BCMA ANKET) in autoimmune indications under the agreement. Additionally, Sanofi and Innate agreed to terminate the 2016 Agreement regarding SAR'579/IPH6101 (CD123 ANKET); Innate will regain its rights on SAR'579/IPH6101. As part of these discussions, Sanofi and Innate have agreed to Sanofi's potential investment of up to 15 million euros in new shares of Innate. If the ongoing market conditions are satisfactory, the size and price of this equity investment will be determined. Price Action: SNY stock is down 0.83% to $52.58 at the last check on Thursday. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? SANOFI (SNY): Free Stock Analysis Report This article French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
&w=3840&q=100)
Business Standard
24-04-2025
- Business
- Business Standard
Investors rush to buy Sanofi India shares ahead of ex-dividend date; detail
Sanofi India Share Price, Dividend News: The shares of pharmaceutical company Sanofi India were in demand on the bourses on Thursday, April 24, 2024, ahead of their ex-dividend date. The company's share price advanced 4.39 per cent to ₹6,717.5 per share on the BSE during intra-day deals on Thursday. The company's shares continued to trade higher, and as of 1:27 PM on Thursday, they were quoted at ₹6,633.65 per share, up 3.09 per cent from the previous close. The upward movement in the company's share price aligns with the company's announcement of dividend rewards for its shareholders. Notably, the company's shares are set to trade ex-dividend tomorrow, April 25, 2024. The ex-dividend date marks the day a stock begins trading without the right to receive the declared dividend, meaning investors must own the stock before this date to be eligible. In an exchange filing, Sanofi India informed the bourses that its board has recommended a final dividend of ₹117 per equity share of the face value of ₹10 each for the financial year ended December 31, 2024. This, however, remains subject to the approval of shareholders at the ensuing 69th Annual General Meeting. Also Read: The pharmaceutical company has set Friday, April 25, 2025, as the record date to ascertain the shareholders' eligibility for the dividend payment. The company will finalize the list of eligible shareholders based on their records on the record date. Also Read At the current market price, Sanofi India's dividend yield stands at 1.77 per cent. Sanofi India dividend history: The pharmaceutical company has consistently rewarded its shareholders with dividend payouts. According to BSE data, Sanofi India paid an interim dividend of ₹50 per share and a final dividend of ₹117 per share in 2024. Earlier, in 2023, Sanofi India paid a special dividend of ₹183 per share and a final dividend of ₹194 per share to its shareholders. Historically, Sanofi India shares have exhibited mixed performance over the past year. The company's share price has advanced nearly 13 per cent in the last one month and 3 per cent in the last six months, while it has dropped nearly 19 per cent over the last year. Sanofi India shares have posted a gain of 9 per cent year-to-date, whereas the Sensex has advanced nearly 2 per cent this year. Sanofi India's shares have a 2-week range of ₹7,593.60 - ₹4,145.90 on the BSE. About Sanofi India: Sanofi India is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has its own manufacturing facilities in Goa and Ankleshwar, Gujarat. The pharmaceutical company sells products through independent distributors, primarily in India. Sanofi India's products, such as Lantus, Combiflam, Amaryl, and Allegra, feature in the top 100 pharmaceutical brands in India.
